-
MicroPort NeuroTech Lists in Hong Kong with $43.3 Million IPO
•
MicroPort NeuroTech Limited has successfully completed its initial public offering (IPO) on the Hong Kong Stock Exchange, issuing 13.7 million shares at HKD 24.64 (USD 3.40) per share, raising a total of HKD 340 million (USD 43.3 million). This milestone underscores the company’s significant valuation of USD 1.75 billion upon…
-
Bayer’s Kerendia Approved by China’s NMPA for Diabetic Kidney Disease
•
The National Medical Products Administration (NMPA) has approved Bayer’s (ETR: BAYN) Category 1 drug Kerendia (finerenone) for adult patients with chronic kidney disease (CKD) associated with type 2 diabetes. This approval marks a significant advancement in the treatment of diabetic kidney disease, offering a new option to slow disease progression…
-
Hengrui Medicine’s SHR3680 Approved for High Burden Metastatic Prostate Cancer
•
China’s Hengrui Medicine Co., Ltd. (SHA: 600276) announced that its Category 1 drug SHR3680 has received conditional approval from the National Medical Products Administration (NMPA) via priority review procedures. The drug is now approved for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) with high tumor burden. Mechanism and AdvantagesSHR3680…
-
Legend Biotech Collaborates with Trinity College Dublin on CAR-T Therapies for Solid Tumors
•
China-based Legend Biotech Corporation (NASDAQ: LEGN) has formed a partnership with Trinity College Dublin and Saint James’s Hospital in Ireland to develop 3D models for exploring chimeric antigen receptor T-cell (CAR-T) therapies in solid tumors. This collaboration, focusing on lung, colorectal, and gastric cancers, aims to create three types of…
-
AnchorDx and West China Hospital Collaborate on Lung Cancer Early Diagnosis
•
Guangzhou-based AnchorDx and West China Hospital of Sichuan University have entered into a transfer agreement for their joint patent on methylation molecular markers for detecting benign and malignant pulmonary nodules. This collaboration aims to enhance the early diagnosis of lung cancer and improve the diagnostic rate of fiberoptic bronchoscopy. Collaboration…
-
Akeso Biopharma’s Cadonilimab Approved for Cervical Cancer Treatment
•
China-based biotech company Akeso Biopharma (HKG: 9926) announced that its self-discovered bispecific antibody (BsAb) cadonilimab (AK104) has received conditional market approval from the National Medical Products Administration (NMPA). The drug is indicated for the treatment of recurrent or metastatic cervical cancer that has failed previous platinum-based chemotherapy. Drug Profile and…
-
Humanwell Healthcare Wins NMPA Approval for RFUS-144 in Pain Management
•
China-based Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) announced receiving approval from the National Medical Products Administration (NMPA) to initiate a clinical study for its Category 1 drug RFUS-144, designed to relieve pain and itching. This marks a significant step forward in the company’s efforts to develop innovative therapies for…
-
LaNova Medicines Secures Series B Funding to Advance Oncology Pipeline
•
China-based LaNova Medicines has successfully closed a Series B financing round, raising an undisclosed sum to support its ongoing research and development efforts. The round was co-led by Qiming Venture Partners, Summer Capital, and Taikun Fund, with participation from the Shanghai Biomedicine Fund. The funds will be dedicated to advancing…
-
GenFleet Collaborates with BioLineRx to Develop Motixafortide for Pancreatic Cancer in China
•
China-based GenFleet Therapeutics has entered into a collaboration with Israel’s BioLineRx Ltd (NASDAQ: BLRX) to advance the development of motixafortide, a C-X-C chemokine receptor type 4 (CXCR4) inhibitor, for the treatment of pancreatic ductal adenocarcinoma (PDAC) in China. This partnership underscores GenFleet’s commitment to bringing innovative oncology therapies to Chinese…
-
Henlius and Palleon Partner on HER2-Targeted Antibody-Sialidase Fusion Protein
•
China-based Shanghai Henlius Biotech Inc. (HKG: 2696) announced a strategic partnership with US-based Palleon Pharmaceuticals Inc. to jointly develop and commercialize two bifunctional antibody-sialidase fusion proteins. This collaboration leverages Palleon’s innovative Enzyme-Antibody Glyco-Ligand Editing (EAGLE) platform, designed to enhance antitumor immunity by removing immunosuppressive sialic acids from tumor and immune…
-
Lundbeck Initiates TALISMAN Study on Multiple System Atrophy in China and EU
•
Danish-based Lundbeck (OTCMKTS: HLUBF) has announced plans to initiate a global investigational study on multiple system atrophy (MSA), named TALISMAN. The trial will be conducted at sites in China and the European Union, marking a significant step in understanding and addressing this rare neurodegenerative disease. Disease BackgroundMSA is a rare,…
-
OCON Healthcare Partners with Bio Genuine for China Marketing Rights and Women’s Health Product Development
•
Israel-based OCON Healthcare, a specialist in uterine drug delivery, has entered into a license agreement with China’s BioGenuine. The deal grants BioGenuine exclusive marketing rights to OCON’s products in China and establishes a partnership for co-development and commercialization of new women’s health products. Deal TermsBioGenuine will pay an upfront fee…
-
Expeclinlab Raises RMB 185 Million to Boost Clinical Mass Spectrometry Business
•
Focused Photonics Inc’s (SHE: 300203) subsidiary Expeclinlab has secured RMB 185 million (USD 27.7 million) in its latest funding round. The investment was led by Sequoia Capital China, Shandong Huiyuan Technology Development Co., Ltd, and four other investors, with proceeds earmarked to accelerate business development. Expeclinlab’s Specialization and ProductsExpeclinlab, a…
-
Beijing Luzhu Biotechnology Secures Series C Funding for Meningococcal Vaccine Development
•
China-based Beijing Luzhu Biotechnology Co., Ltd has reportedly secured an undisclosed amount in a Series C (crossover) financing round led by Huapu Haihe Biomedical Fund, Yizhuang Biomedical Fund, and CNCB (Beijing) Equity Investment Fund. This latest funding follows previous rounds including RMB 350 million (USD 52.3 million) in Series B…
-
Eli Lilly’s Donanemab Receives Tacit Approval for Alzheimer’s Clinical Trial in China
•
The Center for Drug Evaluation (CDE) website indicates that US major Eli Lilly’s (NYSE: LLY) donanemab has obtained tacit clinical trial approval for assessment in treating early symptomatic Alzheimer’s disease (AD), including mild cognitive impairment due to AD, and mild AD. This approval marks a significant step forward in the…
-
Hainan Lecheng Partners with Fosun Pharma on Innovative Medical Devices and Diagnostics
•
The Hainan Boao Lecheng International Medical Tourism Pilot Zone Administration has formed a partnership with Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) to translate scientific research achievements into commercial products. This collaboration aims to advance the development and commercialization of innovative medical technologies. Collaboration Focus AreasThe partnership…
-
Recbio’s R520A mRNA COVID-19 Vaccine Receives Clinical Approval in the Philippines
•
China-based Jiangsu Recbio Technology Co., Ltd has announced receiving clinical trial approval from the Food and Drug Administration of the Philippines for its mRNA COVID-19 vaccine R520A. This approval marks a significant milestone in the global rollout of Recbio’s innovative vaccine targeting the Omicron variant. Vaccine InnovationR520A, developed by Wuhan…
-
Pfizer’s Besponsa First Prescribed in China for Leukemia Treatment
•
US major Pfizer (NYSE: PFE) has announced the first prescriptions for its leukemia therapy Besponsa (inotuzumab ozogamicin) in multiple cities in China. This marks the official application of the world’s first antibody drug conjugate (ADC) in relapsed or refractory precursor B-cell ALL (R/R B-ALL). Mechanism of ActionBesponsa targets CD22, which…
-
Kelun Pharmaceutical Receives USD 30 Million from MSD for Licensing Deal
•
China-based Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) has announced receiving USD 30 million from US major Merck Sharp & Dohme (MSD), triggered by a licensing agreement reached on May 16, 2022. This payment is part of a broader collaboration between the two companies to develop and commercialize an innovative…
-
ImmuneOnco Biopharmaceuticals Files for HKSE IPO with Comprehensive Tumor Immunotherapy Pipeline
•
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd has submitted an initial public offering (IPO) filing to the Hong Kong Stock Exchange (HKSE). The tumor immunotherapy-focused biotech company boasts a comprehensive product pipeline of over 10 drug candidates targeting innate and adaptive immune checkpoints. Five candidates are currently the focus of seven separate…
